Form 4: Amgen SVP Miller Sells Shares for Tax Obligations

Amgen's SVP of Human Resources, Derek Miller, disposed of 1,616 shares of common stock at $366.21 per share to cover tax liabilities related to equity vesting.

Summary

• Derek Miller, SVP, Human Resources at Amgen Inc., reported a transaction involving the company's common stock.
• On March 16, 2026, Miller disposed of 1,616 shares of Amgen common stock.
• The shares were disposed of at a price of $366.21 per share.
• This transaction is identified by transaction code 'F', which typically indicates a payment of tax liability by delivering or withholding securities incident to the vesting of a restricted stock unit or the exercise of a stock option.
• Following this transaction, Miller beneficially owns 12,173 shares of Amgen common stock directly.
• The beneficially owned shares include 197 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis according to the vesting schedule.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine insider transaction for tax purposes rather than a strategic move or a reflection of company performance.

Positives

• The executive received equity compensation, demonstrating a compensation structure that includes stock-based incentives.
• The executive retains a substantial beneficial ownership of 12,173 shares, indicating continued alignment with shareholder interests.

Negatives

• The disposition of 1,616 shares, while for tax purposes, represents a reduction in the executive's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, often related to executive compensation and tax planning, and do not typically reflect a change in the company's fundamental business operations or strategy. This transaction is a routine compliance event within the pharmaceutical and biotechnology industry.

Comparison to Industry Standards

• This Form 4 filing represents a standard regulatory disclosure for insider transactions, a common occurrence across publicly traded companies.
• The 'sell to cover' transaction type, used to satisfy tax obligations from equity vesting, is a widely accepted practice for executives and aligns with typical corporate governance and compensation structures in the U.S. market.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership changes, which is a routine disclosure and generally has minimal direct impact on share price unless the transaction is unusually large or indicative of a change in executive confidence.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by an executive to satisfy tax obligations upon the vesting of equity awards. Such transactions are common and generally do not indicate a change in the company's fundamental prospects or warrant a shift in investment strategy. The executive still retains a significant number of shares, maintaining alignment with shareholder interests.

Keywords

Amgen, AMGN, insider trading, Form 4, stock sale, executive compensation, Derek Miller, human resources, equity vesting, tax obligations